Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Pancreatic cancer breakthrough drug Rasonque doubles survival time in trial

27 August 2026 · By · Wire by Fusion42

Published

27 August 2026

Topic

opportunities

◆ Sectors

BiotechDrug Discovery

◆ Geography

United States

◆ Source

Read at foxnews.com →

◆ Verified

Fusion42 · 27 August 2026 · Fusion42 review

Clinical trial results for Rasonque, a new drug from Revolution Medicines, show it doubles survival time in stage 4 pancreatic cancer patients to 13.2 months compared to 6.7 months with chemotherapy.

This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery.

◆ ◆ The Wire takeaway

Biotech founders focused on oncology can leverage this clinical success to attract partnerships or accelerate development pipelines. Rapidly advancing treatment options disrupt existing chemotherapy reliance and open patient access to more effective therapies.

◆ Coverage

1 source · 27 Aug 2026

◆ Related on Wire

◆ Topics

BiotechDrug Discoverypancreatic-cancerclinical-trialbiotechcancer-treatmentdrug-development